UNSPSC 51284120: Ceftizoxime

This classification denotes an anti-bacterial agent with the molecular formula C13H13N5O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C43C467DPE, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))- but generally known as ceftizoxime, which bears US NIH Compound Identifier 6533629. European Medicines Agency schedules Ceftizoxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07429MIG.

UNSPSC 51284120 Ceftizoxime is a Commodity code that nominally names a specific antibiotic pharmaceutical, but recent state and local solicitations tagged to this code show minimal actual procurement activity for the named product. The source contains one Ceftizoxime-specific opportunity and three opportunities unrelated to ceftizoxime or its pharmaceutical class — a naloxone and drug deactivation systems purchase, a direct-to-manufacturer prescription program request for information, and a medical and first aid supplies bid for emergency response equipment. The mismatch between the code's nominal scope and the actual work posted suggests either a data tagging error in the state and local procurement systems or that this code serves as a catch-all pharmaceutical bucket with inconsistent application. State and local governments do procure specific branded and generic pharmaceuticals through formal IFB, RFP, and cooperative purchasing vehicles, but the current record does not support meaningful activity concentration under this code.

Recent opportunities show activity from a county health department (Seminole County, Florida seeking naloxone), a state health commission (Texas HHS seeking direct-manufacturer prescription logistics), a municipal fire department (City of Tampa seeking emergency medical supplies), and a multistate cooperative purchasing alliance (MMCAP, Minnesota, seeking generic pharmaceuticals). Geographic spread includes Florida, Texas, Minnesota, and Oregon. The most relevant recent opportunity is the City of Tampa's March 2026 IFB (26P00145) for medical and first aid supplies, due March 13, 2026, estimated at $700,000.00 with a certified Small Local Business Enterprise set-aside and 5 percent discount; another is MMCAP's January 2026 RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, proposals due March 26, 2026, with awards effective July 1, 2026. No specific recent opportunities matching ceftizoxime procurement appear in the source.